Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2020

View Archived Issues

Degradation approach targets extracellular proteins

Honest placebos change brain potentials

Phase II trial of VIR-2218 plus peg-IFN-alfa 2a recruits patients with HBV infection

Genentech opens phase I study of GDC-6036 KRAS G12C mutation solid tumors

PDE5 inhibitor AR-1001 affects mechanisms involved in Alzheimer's disease

Cadila Healthcare patents NLRP3 inflammasome inhibitors

Further signs of efficacy seen in trial of AstroRx in amyotrophic lateral sclerosis

Roche patents new HBV antivirals

Nanjing TransThera Biosciences identifies AOC3 inhibitors

Innovative phase III study assesses LY-CoV555 for preventing SARS-CoV-2 infection in care facilities

French researchers disclose TfR1-targeting antibodies

Novartis synthesizes mTORC1 inhibitors

Encouraging topline phase III results reported for seladelpar in primary biliary cholangitis

Tasquinimod treatment begins in phase Ib/IIa multiple myeloma study

Alzheimer's blood test could improve trials, help find treatments

Phase II study begun for Zhifei Longcom's recombinant coronavirus vaccine

Data presented for factor XIa inhibitor milvexian in thrombosis models

FDA approves IND for phase II study of varoglutamstat in Alzheimer's disease

Variants in CD55 gene may cause protein-losing enteropathy

NTR-441 developed to clear neutrophil extracellular traps in severe cases of COVID-19

Spravato antidepressant nasal spray approved in the U.S. for MDD with suicidal ideation

Phase II study evaluates BMS-986278 in lung fibrosis

FDA issues complete response letter for Viaskin Peanut

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...